EUCTR2012-004847-61-GB进行中（未招募）不适用
A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI - INSPIRE (Isentress Pilot Study in Relapsing MS)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients between 18-55 years of age.
- •Diagnosis of MS, according to the revised McDonald Criteria 2010.
- •EDSS score of 0-6.0 inclusive.
- •Documented at least one relapse within the past 12 months or at least one Gd-enhanced lesion on the brain MRI. detected within 3 months prior to screening date
- •Gd-enhanced lesion on screening MRI if MRI not used to meet screening criteria above.
- •Female patients of childbearing potential will be expected to be on appropriate contraception (hormonal or barrier method of birth control; abstinence) from time of consent until 6 weeks after treatment discontinuation. (the repeated administration of gadolinium and MRI are not recommended during pregnancy). NOTE: Subjects are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.
- •Females of childbearing potential must have a negative urine pregnancy test prior to every MRI scan/ within 7 days prior to being registered for protocol therapy.
- •Must give written informed consent and authorize the release and use of protected health information, as required by local law.
- •Able and willing to undergo blood, saliva and urine sampling at regular intervals as defined by the protocol.
- •Able and willing to receive Gadolinium enhanced MRI’s at regular intervals as defined by the protocol.
- •Able to comply with study requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Pregnant or breastfeeding or unwilling to use contraception.
- •Treatment with immunosuppressive, immunomodulatory or experimental treatments within the last 6 months of enrolment in the study, but excluding pulsed intravenous or oral steroids for treatment of MS relapse.
- •No pulsed intravenous or oral steroids in the 30 days preceding the baseline assessment.
- •Patients presenting with medical disorder deemed severe or unstable by the CI such as poorly controlled diabetes or arterial hypertension, severe cardiac insufficiency, unstable ischemic heart disease, abnormal liver function tests (>2.5 times ULN) and abnormal complete blood count (in particular leukopenia, as defined by a lymphocyte count <500, neutrophil <1.5 or platelet count < 100, or thrombocytopenia < 1.5 LLN), or any medical condition which, in the opinion of the chief investigator, would pose additional risk to the patient.
- •Presence of human immunodeficiency virus antibodies.
- •Patients receiving proton pump inhibitors (e.g. omeprazole/esomeprazole)
- •Patients with active hepatitis B or/and C with liver function tests >2.5 times ULN
- •Exposure to any other investigational drug within 30 days of enrolment in the study.
- •Prior history of malignancy unless an exception is granted by the Chief Investigator.
- •History of uncontrolled drug or alcohol abuse within 6 months prior to enrolment into the study.
- •Patients treated with Rifampicin in past four weeks.
研究者
相似试验
已完成
不适用
A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRITopic: NeurologicalSubtopic: Neurological (all Subtopics)Disease: Nervous system disordersNervous System DiseasesISRCTN82487767Queen Mary University of London (UK)31
进行中（未招募）
1 期
_Patients with liver-only non resectable colorectal metastases.EUCTR2016-001493-15-FRICANCER140
已完成
2 期
Phase2 study on the validity of initiating treatment during midtrimester for GDM patientsGDMJPRN-UMIN000030231Yokohama City University Medical Center150
尚未招募
2 期
Study of effect of siddharthakadi lepa and vamankarma in volunteers having pimplesCTRI/2020/11/028881Dr Shraddha Dnyandev Patil
尚未招募
2 期
A Comparison of effect of Kantakaryadi Kwatha and Bhunimbadi Kwatha in AcidityCTRI/2020/09/028034Ayurved Mahavidyalaya Nashik